Delving into the Latest Updates on Next generation compounds(Tranquis Therapeutics) with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesNervous System Diseases

Active Indication

Immune System DiseasesNervous System Diseases

Inactive Indication-

Originator Organization

Tranquis Therapeutics, Inc.Startup

Active Organization

Tranquis Therapeutics, Inc.Startup

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

Using radioligand receptor binding assay (RRA), dopamine receptor in the calf caudate were identified with 3H-Spiperone as radioactive ligand. The total number of maximal binding sites (Bmax), the equilibrium dissociation affinity (Kd), the concentrations of drug required to inhibited 50% specific binding (Ic50) and competitive inhibition constant (Ki) of antipsychotics in calf caudate were determined by sturative binding experiment and inhibitive binding experiment. The result showed the mean Bmax was 0.659 pmol/mg protein membrane and Kd was 0.31 nmol/L. Scatchard analysis denotes that it was hyperbole and there were two binding positions in calf caudte. Antipsychotics can inhibit 3H-Spiperone binding specifically the order of affinity constants (1/Ki) was Haloperdol and sulpiride, Chlorpromazine and Clozapin, Tranquis and Taractan. This abilities of drugs to compete with 3H-Spi binding will be used as basis of RRA for measuring blood levels of antipsychotics.

100 Deals associated with Next generation compounds(Tranquis Therapeutics)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immune System Diseases	Discovery	-	Tranquis Therapeutics, Inc.Startup	25 Apr 2022
Nervous System Diseases	Discovery	-	Tranquis Therapeutics, Inc.Startup	25 Apr 2022